Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Yukiko Kanda-Kimura"'
1
Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β-cells in db/db mice: The earlier and longer, the better
Autor: Kenji Kohara, Tomohiko Kimura, Atsushi Obata, Shuhei Nakanishi, Saeko Moriuchi, Hideaki Kaneto, Tomoatsu Mune, Hidenori Hirukawa, Yukiko Kanda-Kimura, Yuka Nogami, Masashi Shimoda, Kohei Kaku, Seizo Okauchi
Publikováno v: Diabetes, Obesity and Metabolism. 20:2442-2457
Aims We compared the protective effects of sodium glucose co-transporter (SGLT) 2 inhibitor luseogliflozin on pancreatic β-cells between early and advanced stages of diabetes and between short- and long-term use. Materials and methods Diabetic db/db
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58d5118ba4b1ee38e191433dac838785
https://doi.org/10.1111/dom.13400
Zobrazit plný text záznamu
3
Seven-year Observational Study on the Association between Glycemic Control and the New Onset of Macroangiopathy in Japanese Subjects with Type 2 Diabetes
Autor: Hideaki Kaneto, Masashi Shimoda, Shinji Kamei, Tomohiko Kimura, Kohei Kaku, Takatoshi Anno, Mitsuru Hashiramoto, Michihiro Matsuki, Fumiko Kawasaki, Tomoatsu Mune, Yukiko Kanda-Kimura
Publikováno v: Internal Medicine. 55:1419-1424
Objective To examine the association between glycemic control and the new onset of macroangiopathy in Japanese subjects with type 2 diabetes. Methods We examined seven-year follow-up data for 572 patients. We divided the subjects by the average of se
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1330613b75b3de25bce73962c5a732b
https://doi.org/10.2169/internalmedicine.55.4952
Zobrazit plný text záznamu
4
Influence of atherosclerosis‐related risk factors on serum high‐sensitivity C‐reactive protein levels in patients with type 2 diabetes: Comparison of their influence in obese and non‐obese patients
Autor: Hideaki Kaneto, Hidenori Hirukawa, Kenji Kohara, Tomohiko Kimura, Fumiko Kawasaki, Tomoatsu Mune, Yukiko Kanda-Kimura, Masashi Shimoda, Shinji Kamei, Kohei Kaku, Seizo Okauchi, Hiroshi Yoshioka
Publikováno v: Journal of Diabetes Investigation
Aims/Introduction Increased levels of high-sensitivity C-reactive protein (hs-CRP) likely leads to the development of atherosclerosis. Therefore, it is very important to know which factors largely influence hs-CRP levels. In the present study, we exa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b4793507922c18fceb01d640ebb4181
https://doi.org/10.1111/jdi.12388
Zobrazit plný text záznamu
5
Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytes
Autor: Masafumi Matsuda, Kohei Kaku, Masashi Shimoda, Shinji Kamei, Yukiko Kanda-Kimura, Fuminori Tatsumi, Atsushi Obata, Sumiko Hamamoto, Tomoatsu Mune, Tomohiko Kimura, Mitsuru Hashiramoto, Hideaki Kaneto, Kazuhito Tawaramoto
Publikováno v: Endocrine Journal. 62:741-747
It is known that reactive oxygen species (ROS) are involved in the development of insulin resistance as well as pancreatic β-cell dysfunction both of which are often observed in type 2 diabetes. In this study, we evaluated the effects of azelnidipin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a40997871bc62292cba804090fa3d44a
https://doi.org/10.1507/endocrj.ej15-0273
Zobrazit plný text záznamu
6
Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure
Autor: Shuhei Nakanishi, Kohei Kaku, Kenji Kohara, Hideaki Kaneto, Yuka Nogami, Tomohiko Kimura, Tomoatsu Mune, Hidenori Hirukawa, Atsushi Obata, Yukiko Kanda-Kimura, Masashi Shimoda
Publikováno v: Diabetesmetabolism. 44(3)
Aims It is well-known that chronic exposure to large amounts of ligand leads to downregulation of its receptor. It is not known, however, whether a GLP-1R agonist downregulates its receptor. For this reason, our study examined whether GLP-1R expressi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c74a30021f42e7035ab5ad0b64882172
https://pubmed.ncbi.nlm.nih.gov/29525225
Zobrazit plný text záznamu
7
Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus
Autor: Fumiko Kawasaki, Tomoatsu Mune, Kazuhito Tawaramoto, Hidenori Hirukawa, Mitsuru Hashiramoto, Masashi Shimoda, Tomohiko Kimura, Yukiko Kanda-Kimura, Takatoshi Anno, Kohei Kaku, Michihiro Matsuki, Fuminori Tatsumi
Publikováno v: Diabetes Research and Clinical Practice. 101:35-44
To evaluate the efficacy of miglitol and mitiglinide alone or in combination on the metabolic profile and incretin secretion in Japanese type 2 diabetes patients.Patients on diet and exercise with or without metformin, were randomized to receive eith
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::456087a38f47cb72e4f7471c07205bca
https://doi.org/10.1016/j.diabres.2013.04.007
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje